L-Carnitine Rompharm, 200 mg/ml 5 ml 5 pcs

Pharmacotherapeutic group:metabolic agent.

ATX code: A16AA01

Pharmacological action

Levocarnitine is a metabolic remedy; Has metabolic, anabolic, antihypoxic and antithyroid effect, activates fat metabolism, stimulates regeneration, increases appetite. Levocarnitine – a natural substance related to the B vitamins. It is a cofactor of metabolic processes to maintain the activity of coenzyme A (CoA).

Limits basic metabolism, slows down the breakdown of protein and carbohydrate molecules. It promotes penetration through mitochondrial membranes and the breakdown of long-chain fatty acids (palmitic acid and others) to form acetyl-CoA (necessary for pyruvate carboxylase activity during gluconeogenesis, ketone bodies formation, synthesis of choline and its esters, oxidative phosphorylation and formation of adenosine triphosphate (ATP). Mobilizes fat (presence of 3 labile methyl groups) from fat depots. It competitively displaces glucose and promotes fatty acid metabolic shunt, which activity is not limited by oxygen (unlike aerobic glycolysis). Therefore, the drug is effective under conditions of acute hypoxia (including brain) and other critical conditions.

It causes slight inhibition of the central nervous system (CNS), increases the secretion and enzymatic activity of digestive juices (gastric and intestinal), improves digestion.

Limits excess body weight and reduces fat in the skeletal muscles.

Enhances resistance to exercise, reduces lactate acidosis and regenerates ability to work after prolonged physical activity. At the same time it promotes economical use of glycogen and increases its reserves in the liver and muscles.

It has a neurotrophic effect, inhibits apoptosis, limits the affected area and restores the structure of nervous tissue.

Normalizes protein and fat metabolism, increased basic metabolism in thyrotoxicosis (being a partial antagonist of thyroxine); restores the alkaline reserve of the blood.

Pharmacokinetics

After intravenous administration, it disappears from the blood after 3 hours. Easily penetrates into the liver and myocardium, slower in muscles.

Extracted by the kidneys mainly as acyl esters (more than 80% in 24 hours).

Indications

L-Carnitine Romfarm is used as part of complex therapy in acute hypoxic states (acute cerebral hypoxia, ischemic stroke, transient ischemic attack). The drug is prescribed in acute, subacute and recovery periods of cerebral circulation disorders. It is used for discirculatory encephalopathy and various traumatic and toxic lesions of the brain, in the recovery period after surgical interventions.

L-Carnitine by Romfarm is indicated in primary and secondary carnitine deficiency, including patients with chronic renal failure, those on hemodialysis, in cardiomyopathy, coronary heart disease (angina, acute myocardial infarction, postinfarction conditions), hypoperfusion due to cardiogenic shock and other disorders of myocardial metabolism.

Active ingredient

Composition

1 ml of the drug contains:

acting substance:

levocarnitine – 200.0 mg;

excipients: 1 M hydrochloric acid solution – to pH 6.3 – 6.5, water for injection – to 1.00 ml.

How to take, the dosage

L-Carnitine Rompharm is administered intravenously by slow drip or stream (2-3 min) or intramuscularly. Before intravenous injection, the contents of the ampoule are dissolved in 100-200 ml of solvent (0.9% sodium chloride solution or 5% dextrose (glucose) solution).

In acute disorders of cerebral circulation 1 g/day is prescribed for 3 days, and then 0.5 g/day for 7 days. After 10-12 days repeated courses of 3-5 days are possible.

When the drug is prescribed in the subacute and recovery period, in discirculatory encephalopathy and various brain lesions, carnitine deficiency patients are given levocarnitine solution at a rate of 0.5-1 g/day intravenously (drop or stream) or intramuscularly (2 to 3 times a day) without dilution for 3-7 days. If necessary in 12-14 days a repeated course is prescribed.

Intravenous administration, slowly (2-3 min) is administered in secondary carnitine deficiency during hemodialysis – 2 g once (after the procedure); during acute myocardial infarction, acute heart failure – 3-5 g/day, divided into 2-3 doses during the first 2-3 days with subsequent reduction of the dose by 2 times; during cardiogenic shock – 3-5 g/day, divided into 2-3 doses until the patient comes out of shock. Then switch to oral administration of levocarnitine.

Interaction

Special Instructions

L-Carnitine Rompharm is not addictive because levocarnitine is endogenous.

The increase in glucose absorption when L-Carnitine Rompharm is given to diabetic patients receiving insulin or oral hypoglycemic drugs may cause hypoglycemia. Therefore, during treatment with L-Carnitine Romfarm, blood glucose should be monitored constantly in these patients to allow for immediate correction of the dosing of hypoglycemic drugs.

Long-term use of levocarnitine at high doses in patients with significant renal impairment may increase concentrations of the potentially toxic metabolites, trimethylamine and trimethylamine-N-oxide, because these metabolites are typically excreted in the urine. In this case, urine, breath, and sweat secretions have an unpleasant odor.

If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.

Influence on driving and operating ability

The drug does not affect the ability to drive and other potentially dangerous activities.

Synopsis

Contraindications

Hypersensitivity to levocarnitine or other components of the drug, pregnancy and breastfeeding.

With caution the drug should be prescribed in diabetes mellitus.

Side effects

Mild symptoms of myasthenia gravis were observed only in uremic patients taking levocarnitine. Allergic reactions.

In fast administration (80 drops/min or more), vein pain may occur, which resolves with a reduction in the rate of administration.

Overdose

There are no data on toxicity in case of levocarnitine overdose. Tolerability of the drug should be monitored during the first week of administration and after each dose increase.

In case of overdose, treatment to maintain vital functions, symptomatic treatment is prescribed.

Pregnancy use

Similarities